Lucentis enrollment timeline slips for a third time:
According to Wednesday’s DNA CC, full enrollment for the phase-3 trial Lucentis in predominantly-classic AMD has now slipped from 1H04 (which actually means 2Q04) to “mid” 2004 (which means 3Q04) to 2H04 (which, of course, means 4Q04).
(The other phase-3 Lucentis trial, in minimally-classic/occult AMD completed enrollment behind its original schedule in late 2003.)
It seems that patients just don’t like getting poked in the eye every month, especially when some of the pokes result in serious inflammation.
Market Data 
Markets 
AI
